An eye-opening social media reel has gone viral, showcasing the drastic variation in cancer medication prices between India and the United States. It highlights how a vital blood cancer drug, Revlimid, is available in India at a much lower cost as a generic version compared to its expensive branded form in the US. This stark contrast has prompted a robust online dialogue about the state of global healthcare affordability.
